Pfizer (PFE) Cash & Equivalents (2009 - 2026)

Pfizer (PFE) has 18 years of Cash & Equivalents data on file, last reported at $1.7 billion in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $1.7 billion, up 19.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 19.09% YoY), and the FY2025 annual result was $1.1 billion, up 9.49% from the prior year.
• Cash & Equivalents grew to $1.7 billion in Q1 2026 per PFE's latest filing, from $1.1 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $3.1 billion in Q4 2023 and troughed at $416.0 million in Q4 2022.
• A 5-year average of $1.6 billion and a median of $1.4 billion in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 78.6% in 2022, then jumped 585.82% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $416.0 million in 2022, then jumped by 585.82% to $2.9 billion in 2023, then slumped by 63.44% to $1.0 billion in 2024, then rose by 9.49% to $1.1 billion in 2025, then soared by 49.12% to $1.7 billion in 2026.
• Business Quant data shows PFE's Cash & Equivalents at $1.7 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.3 billion in Q3 2025.